Patents by Inventor Xixi Feng

Xixi Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective FKBP51 ligands for treatment of psychiatric disorders
    Patent number: 10246413
    Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 2, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20180072667
    Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 15, 2018
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • Selective FKBP51 ligands for treatment of psychiatric disorders
    Patent number: 9845292
    Abstract: The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 19, 2017
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
  • SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20160289184
    Abstract: The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.
    Type: Application
    Filed: September 15, 2014
    Publication date: October 6, 2016
    Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter